Shire's Investigational Nonstimulant ADHD Treatment INTUNIV TM Demonstrated Significant Efficacy In Reducing ADHD Symptoms

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, presented at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investigational once-daily medication, which is being evaluated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD). ...

Write comment to this article:

Subject:

Name:

email or site:

Code: